Samil Pharm
Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inf… Read more
Samil Pharm (000520) - Net Assets
Latest net assets as of June 2025: ₩149.26 Billion KRW
Based on the latest financial reports, Samil Pharm (000520) has net assets worth ₩149.26 Billion KRW as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩375.58 Billion) and total liabilities (₩226.31 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩149.26 Billion |
| % of Total Assets | 39.74% |
| Annual Growth Rate | 7.77% |
| 5-Year Change | 177.14% |
| 10-Year Change | 223.7% |
| Growth Volatility | 26.67 |
Samil Pharm - Net Assets Trend (2011–2024)
This chart illustrates how Samil Pharm's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Samil Pharm (2011–2024)
The table below shows the annual net assets of Samil Pharm from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩176.12 Billion | +37.78% |
| 2023-12-31 | ₩127.83 Billion | +1.60% |
| 2022-12-31 | ₩125.82 Billion | +91.37% |
| 2021-12-31 | ₩65.75 Billion | +3.45% |
| 2020-12-31 | ₩63.55 Billion | +2.05% |
| 2019-12-31 | ₩62.27 Billion | +11.04% |
| 2018-12-31 | ₩56.08 Billion | +9.61% |
| 2017-12-31 | ₩51.17 Billion | -3.22% |
| 2016-12-31 | ₩52.87 Billion | -2.83% |
| 2015-12-31 | ₩54.41 Billion | -1.81% |
| 2014-12-31 | ₩55.42 Billion | -20.87% |
| 2013-12-31 | ₩70.03 Billion | +11.38% |
| 2012-12-31 | ₩62.87 Billion | -5.60% |
| 2011-12-31 | ₩66.60 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Samil Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1993656137000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩19.94 Billion | 11.32% |
| Other Components | ₩156.19 Billion | 88.68% |
| Total Equity | ₩176.12 Billion | 100.00% |
Samil Pharm Competitors by Market Cap
The table below lists competitors of Samil Pharm ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PLINTAS
KLSE:5320
|
$110.61 Million |
|
Vaibhav Global Limited
NSE:VAIBHAVGBL
|
$110.61 Million |
|
Donglai Coating Technology (Shanghai) Co. Ltd. A
SHG:688129
|
$110.63 Million |
|
AMTD Digital Inc.
NYSE:HKD
|
$110.65 Million |
|
Guangdong Hotata Technology Group Co Ltd Class A
SHG:603848
|
$110.58 Million |
|
LINE Pay Taiwan Limited
TW:7722
|
$110.48 Million |
|
Mountain Commerce Bancorp Inc
OTCQX:MCBI
|
$110.47 Million |
|
Ceres Power Holdings plc
PINK:CPWHF
|
$110.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Samil Pharm's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 127,827,371,780 to 176,123,873,000, a change of 48,296,501,220 (37.8%).
- Net loss of 5,628,801,980 reduced equity.
- Other factors increased equity by 53,925,303,200.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-5.63 Billion | -3.2% |
| Other Changes | ₩53.93 Billion | +30.62% |
| Total Change | ₩- | 37.78% |
Book Value vs Market Value Analysis
This analysis compares Samil Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.28x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.18x to 1.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩4844.18 | ₩10580.00 | x |
| 2018-12-31 | ₩4594.32 | ₩10580.00 | x |
| 2019-12-31 | ₩5082.66 | ₩10580.00 | x |
| 2020-12-31 | ₩5077.90 | ₩10580.00 | x |
| 2021-12-31 | ₩5201.33 | ₩10580.00 | x |
| 2022-12-31 | ₩9021.50 | ₩10580.00 | x |
| 2023-12-31 | ₩8838.55 | ₩10580.00 | x |
| 2024-12-31 | ₩8296.13 | ₩10580.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Samil Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.56%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 2.24x
- Recent ROE (-3.20%) is below the historical average (-2.54%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 11.32% | 8.89% | 0.77x | 1.65x | ₩927.34 Million |
| 2014 | -20.19% | -13.09% | 0.79x | 1.95x | ₩-16.73 Billion |
| 2015 | 1.08% | 0.67% | 0.89x | 1.83x | ₩-4.85 Billion |
| 2016 | 1.68% | 0.92% | 0.96x | 1.91x | ₩-4.40 Billion |
| 2017 | -2.48% | -1.38% | 0.68x | 2.65x | ₩-6.38 Billion |
| 2018 | -15.27% | -9.05% | 0.64x | 2.64x | ₩-14.17 Billion |
| 2019 | 1.26% | 0.65% | 0.66x | 2.95x | ₩-5.44 Billion |
| 2020 | 2.11% | 1.09% | 0.64x | 3.02x | ₩-5.01 Billion |
| 2021 | -8.13% | -3.98% | 0.59x | 3.44x | ₩-11.92 Billion |
| 2022 | -0.02% | -0.02% | 0.50x | 2.84x | ₩-12.61 Billion |
| 2023 | 1.30% | 0.85% | 0.53x | 2.90x | ₩-11.12 Billion |
| 2024 | -3.20% | -2.56% | 0.56x | 2.24x | ₩-23.24 Billion |
Industry Comparison
This section compares Samil Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $199,195,607,822
- Average return on equity (ROE) among peers: 1.78%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Samil Pharm (000520) | ₩149.26 Billion | 11.32% | 1.52x | $110.58 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |